Documente Academic
Documente Profesional
Documente Cultură
Research Student
ADNAN G . KHAN
Research Guide
Seat.no.1806
CAMP, PUNE
2011-2013
INTRODUCTION
PULSATILE DRUG DELIVERY SYSTEM
Pulsatile drug delivery system is a controlled drug delivery system in
02
03
24-h clock diagram of the peak time of selected human circadian rhythm with reference to the day-night cycle
04
A: Ideal sigmoidal release B & C: Delayed release after initial lag time. The first pulsed delivery formulation that released the active substance at a precisely defined time point was developed in the early 1990s. In this context, the aim of the research was to achieve a so-called sigmoidal release pattern (pattern A in Figure).
Thus, the major challenge in the development of pulsatile drug delivery system is to achieve a rapid drug release after the lag time. Often, the drug is released over an extended period of time (patterns B & C in Figure). 05
MERITS: Predictable, reproducible and short gastric residence time Improve bioavailability Limited risk of local irritation No risk of dose dumping Flexibility in design Improve stability DEMERITS: Lack of manufacturing reproducibility and efficacy Batch manufacturing process Higher cost of production Trained/skilled personal needed for manufacturing
06
Introduction to Ranolazine
Category: Calcium channel blocker Mechanism of action of Ranolazine
07
08
09
10
EXPERIMENTAL WORK
Drug characterization
FTIR
FT-IR SEM
11
F1
500 75 25.5 1.5 10
F2
500 75 24 1.5 10
F3
500 30 75 1.5 10
F4
500 28.5 75 1.5 10
F5
500 27 75 1.5 10
F6
500 25.5 75 1.5 10
F7
500 24 75 1.5 10
F8
500 24 75 1.5 10
Talc
Sod.Starch glycolate
3
7.5
3
9
3
3
3
4.5
3
6
3
7.5
3
9
3
9
12
Coating Composition Coating solution polymer and solvent ratios profile (TRIAL BATCHES)
Sr.No 1 2 Ingredient F1 E S 100 : E L 100 DiButylPthalate DiEthylPthalate Isopropyl alcohol Acetone
0.75:0.7 5 1:1 F2 1:1 1:1 F3 1.5:1. 5 1:1 F4 F5 F6 1.75:1.7 5 1:1 F7 1.75:1.7 5 1:1 F8 1:2 1:1
70:30
70:30 70:30
70:30
70:30
70:30
70:30
70:30
13
Formulation of batch
Levels of variable VARIABLES ( -1) X1 X2 23.5 (mg) 1.5 (g) (0) 24.5 (mg) 3 (g) LEVELS (+1) 24 (mg) 4.5 (g)
14
15
Evaluation of tablets
Thickness Hardness Uniformity of weight Uniformity of content Friability In-vitro drug release from tablets Stability studies
16
B. Melting Point:
The melting point of ranolazine was found to be 120C. This was comparable with its
literature value of 118C-122C.
17
C. Solubility Profile
The solubility study of ranolazine in different solvents was studied and is depicted in table below. Solubility profile of Ranolazine The results of solubility profile confirmed that the drugs had considerable solubility in phosphate buffer (P B) 7.5 for which the drugs formulation was being developed
Sr.No. 1. 2 2. 3. 4.
18
D. Micromeritic Properties:
19
E. UV-Visible Spectroscopy:
UV Scan of ranolazine This max value is compellable to that of the literature value i.e. 272 nm. It conforms the identity of ranolazine.
20
F. Calibration Curve
0.7
0.6
0.4
0.3
0.2
0.1
21
Functional groups -NH stretch (amine) -OH stretch (hydroxyl) -C=O stretch (Aliphatic)
22
H.SEM OF RANOLAZINE
23
I. PXRD OF RANOLAZINE
24
Exipient Characterization
A. Organoleptic properties
The Eudragit L and S 100 was subjected to organoleptic evaluation. The results obtained shown in the table below. Organoleptic properties of Eudragit L and S 100
Sr. No 1. 2. 3. 4.
25
B. Solubility study Solubility of Eudragit L and S 100 is checked as follows Solubility of Eudragit L and S 100
Sr. No 1 2 3 Solvents Distilled water Ethanol Chloroform Observations Insoluble Soluble Soluble
4 5
26
27
A. IR spectroscopy
28
29
PRECOMPRESSED PARAMETERS
Batch code F F F F F F F F F 1 2 3 4 5 6 7 8 9
Angle of repose () 24.80.32 27.40.08 28.40.21 28.40.06 25.80.15 26.20.07 28.10.09 27.20.09 26.20.07
Bulk density (g/cm3) 0.490.013 0.510.013 0.470.02 0.550.025 0.490.012 0.440.006 0.510.002 0.540.04 0.440.006
Tapped density (g/cm3) 0.550.014 0.580.002 0.530.012 0.590.0112 0.560.012 0.490.021 0.580.001 0.56 0.013 0.490.021
Carrs index (%) 10.909 12.068 11.320 6.779 12.5 10.204 12.068 12.056 10.204
Hausners ratio 1.122 1.137 1.127 1.072 1.142 1.113 1.137 1.124 1.113
30
*Formulation Code F1
*Uniformity of *Hardness Thickness(mm) (kg/cm2) (SD) (SD) 5.95 0.030 8.6 0.54
F2
F3 F4 F5 F6 F7 F8 F9
5.09 0.081
5.80 0.034 5.90 0.036 5.46 0.050 5.95 0.032 5.80 0.034 5.95 0.030 5.95 0.032
9.9 0.44
11.70.19 8.9 0.26 10.30.57 9.3 0.65 11.70.19 8.6 0.54 9.3 0.65
0.264
0.226 0.247 0.193 0.144 0.226 0.201 0.144
7211.507
6991.000 6981.577 7381.141 7102.141 6991.000 6701.095 7102.141
97.553.07
98.100.32 97.383.11 98.780.76 99.880.16 98.100.32 100.00.77 99.880.16
31
Formulation Code F1 F2 F3 F4 F5 F6 F7 F8 F9
Uniformity of Thickness(mm) 5.96 0.042 5.99 0.038 5.85 0.018 5.89 0.072 5.68 0.056 5.97 0.033 5.85 0.018 5.96 0.042 5.97 0.033
Hardness (kg/cm2)
10.5 0.55 9.9 0.84 11.7 0.24 10.5 0.63 9.8 0.11 11.1 0.14 11.7 0.24 10.5 0.55 11.1 0.14
Weight variation
7400.085 7331.024 7461.021 7520.099 7481.018 7291.028 7461.021 7400.085 7291.028
32
First Order
F1 F2 F3 F4 F5 F6 F7 F8 F9
Higuchi Matrix Model 0.9011 0.8381 0.8398 0.8406 0.8433 0.8414 0.9340 0.9390 0.8452
Peppas Plot
Hixson Crowell
n Value
33
34
20
10 0 1 2 3 4 5 6 7 8 9 10 11 12
Plot of cumulative %release against time in ranolazine pulsatile tablets (trial batches)
Sr. no. 1 2 3 4 5 6 7 8 9 10 11 Time Hrs 0 1 2 3 4 5 6 7 8 9 10 F1 0 0.124 1.115 3.247 25.222 41.337 55.309 61.474 62.467 71.221 81.247 F2 0 0.103 1.115 3.462 27.664 43.785 51.356 61.68 70.235 74.543 84.256 F3 0 0,009 1.253 3.889 24.221 43.225 49.456 60.38 65.436 76.382 90.12 F4 0 0.091 1.007 2.542 27.654 44.554 61.708 66.436 69.436 77.328 91.35 F5 0 0.098 1.051 2.221 29.985 49.356 62.254 62.989 70.367 83.367 88.25 F6 0 0.103 1.004 2.227 30.542 43.358 55.254 60.36 65.254 85.081 83.778 F7 0 0.008 1.213 3.077 31 53.798 56.947 66.578 72.975 80.173 91.45 F8 0 0.042 1.354 3.116 32.333 55.963 59.47 59.793 73.36 84.507 92.546
35
plot of cumulative %release against time in Ranolazine pulsatile release tablets (factorial batches)
Sr.no 1 2 3 4 5 6 7 8 9 10 Time hr. 0 1 2 3 4 5 6 7 8 9 0 F1 F2 0 F3 0 F4 0 F5 0 F6 0 F7 0 F8 0 F9 0
0.126
1.253 2.507 33.395 48.226 58.54 68.08 71.196 83.563
0.103
1.025 2.621 32.94 48.271 59.656 68.605 72.359 82.427
0.114
1.253 2.735 33.145 48.898 60.454 68.618 73.113 82.988
0.103
1.287 2.963 33.373 49.126 61.708 68.643 73.252 84.744
0.091
1.344 2.849 35.309 52.544 65.13 69.792 74.618 83.367
0.103
1.31 2.621 34.17 51.404 62.849 69.559 74.271 85.081
0.08
1.356 3.077 35.423 53.798 67.637 69.899 75.534 80.173
0.091
1.333 3.191 36.79 55.963 68.211 70.803 76.45 84.507
0.091
1.344 2.849 35.309 52.544 65.13 69.792 74.618 84.164
11
10
98.13
98.906
98.408
98.31
99.221
98.852
95.408
95.761
95.839
36
Regression Analysis:
Response surface plot showing effect of formulation variables on percent drug release (YI) at 10 hr
37
Design-Expert Software Factor Coding: Actual release Design Points 99.22 95.4
4.50
release
3.90
96
B : e u d r a g it
X1 = A: lactose X2 = B: eudragit
3.30
98
97
2.70
2.10
99
96
A: lactose
Contour plot showing effect of formulation variables on cumulative % drug release at 10 hr(Y1)
38
P r e d ic te d
98.00
97.00
96.00
95.00
95.00
96.00
97.00
98.00
99.00
100.00
Actual
Correlation between actual and predicted values for cumulative % drug release at 10 hr (Y1)
39
40
Conclusion
Various approaches were tried for the assessment of pulsatile release of ranolazine with the aid of eudragit L and S 100 as polymers.
No interaction between the drug and excipient was noted, and drug-excipient compatibility study FTIR confirmed no interaction between the drug and polymer.
Pulsatile tablet of ranolazine showed promising results to be a controlled release formulation. Performance enhancement was done by optimization of the proportion of eudragit L and S 100 in the formulation. Selection of optimized batch was done as per performance evaluation. It was observed that in the in-vitro drug release, the batch F 5 possessed the highest potential to release the drug gradually for more than 10 hrs. It was observed from the overall studies that, ranolazine possesses the potential for pulsed release from the tablet.
41
REFERENCES
1. Gothoskar AV, Joshi AM, Joshi NH. Pulsatile drug delivery systems: A review .Drug Delivery Technology 2004;4(5):1-11. 2. Shivakumar HG, Pramodkumar TM, Kashppa GD. Pulsatile drug delivery system, Ind. J. Pham. Educ. 2003;37(3):125 .
42
9. Nash DT, Nash SD. Ranolazine for chronic stable angina. Int. J. Pharm.The Lancet,
43
THANK YOU